Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB). Cefiderocol, a siderophore cephalosporin, represents a novel valuable antimicrobial...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/46/12/846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241975694917632 |
|---|---|
| author | Gabriele Bianco Matteo Boattini Monica Cricca Lucia Diella Milo Gatti Luca Rossi Michele Bartoletti Vittorio Sambri Caterina Signoretto Rossella Fonnesu Sara Comini Paolo Gaibani |
| author_facet | Gabriele Bianco Matteo Boattini Monica Cricca Lucia Diella Milo Gatti Luca Rossi Michele Bartoletti Vittorio Sambri Caterina Signoretto Rossella Fonnesu Sara Comini Paolo Gaibani |
| author_sort | Gabriele Bianco |
| collection | DOAJ |
| description | In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB). Cefiderocol, a siderophore cephalosporin, represents a novel valuable antimicrobial drug for the treatment of infections caused by MDR-GNB. The mechanism of cefiderocol to penetrate through the outer membrane of bacterial cells, termed “<i>Trojan horse</i>”, makes this antimicrobial drug unique and immune to the various resistance strategies adopted by GNB. Its broad spectrum of action, potent antibacterial activity, pharmacokinetics properties, safety, and tolerability make cefiderocol a key drug for the treatment of infections due to MDR strains. Although this novel antimicrobial molecule contributed to revolutionizing the therapeutic armamentarium against MDR-GNB, the recent emergence of cefiderocol-resistant strains has redefined its role in clinical practice and required new strategies to preserve its antibacterial activity. In this review, we provide an updated discussion regarding the mechanism of action, emerging mechanisms of resistance, pharmacokinetic/pharmacodynamic (PK/PD) properties, and efficacy data of cefiderocol against the major Gram-negative bacteria and future prospects. |
| format | Article |
| id | doaj-art-a8298d04109049cc90e757ccee2d28ba |
| institution | OA Journals |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-a8298d04109049cc90e757ccee2d28ba2025-08-20T02:00:25ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452024-12-014612141321415310.3390/cimb46120846Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to CefiderocolGabriele Bianco0Matteo Boattini1Monica Cricca2Lucia Diella3Milo Gatti4Luca Rossi5Michele Bartoletti6Vittorio Sambri7Caterina Signoretto8Rossella Fonnesu9Sara Comini10Paolo Gaibani11Department of Experimental Medicine, University of Salento, 73100 Lecce, ItalyDepartment of Public Health and Paediatrics, University of Torino, 10124 Turin, ItalyDepartment of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum, Section Microbiology, University of Bologna, 40138 Bologna, ItalyDepartment of Biomedical Sciences, Humanitas University, 20089 Milan, ItalyDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, Section Pharmacology, University of Bologna, 40138 Bologna, ItalyDepartment of Diagnostics and Public Health, Microbiology Section, Verona University, 37134 Verona, ItalyDepartment of Biomedical Sciences, Humanitas University, 20089 Milan, ItalyDepartment of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum, Section Microbiology, University of Bologna, 40138 Bologna, ItalyDepartment of Diagnostics and Public Health, Microbiology Section, Verona University, 37134 Verona, ItalyMicrobiology and Virology Unit, Azienda Ospedaliera Universitaria Integrata Di Verona, 37134 Verona, ItalyOperative Unit of Clinical Pathology, Carlo Urbani Hospital, 60035 Jesi, ItalyDepartment of Diagnostics and Public Health, Microbiology Section, Verona University, 37134 Verona, ItalyIn recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB). Cefiderocol, a siderophore cephalosporin, represents a novel valuable antimicrobial drug for the treatment of infections caused by MDR-GNB. The mechanism of cefiderocol to penetrate through the outer membrane of bacterial cells, termed “<i>Trojan horse</i>”, makes this antimicrobial drug unique and immune to the various resistance strategies adopted by GNB. Its broad spectrum of action, potent antibacterial activity, pharmacokinetics properties, safety, and tolerability make cefiderocol a key drug for the treatment of infections due to MDR strains. Although this novel antimicrobial molecule contributed to revolutionizing the therapeutic armamentarium against MDR-GNB, the recent emergence of cefiderocol-resistant strains has redefined its role in clinical practice and required new strategies to preserve its antibacterial activity. In this review, we provide an updated discussion regarding the mechanism of action, emerging mechanisms of resistance, pharmacokinetic/pharmacodynamic (PK/PD) properties, and efficacy data of cefiderocol against the major Gram-negative bacteria and future prospects.https://www.mdpi.com/1467-3045/46/12/846antimicrobialscefiderocolin vitro activitymultidrug resistanceGram-negativeemerging resistance |
| spellingShingle | Gabriele Bianco Matteo Boattini Monica Cricca Lucia Diella Milo Gatti Luca Rossi Michele Bartoletti Vittorio Sambri Caterina Signoretto Rossella Fonnesu Sara Comini Paolo Gaibani Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol Current Issues in Molecular Biology antimicrobials cefiderocol in vitro activity multidrug resistance Gram-negative emerging resistance |
| title | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol |
| title_full | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol |
| title_fullStr | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol |
| title_full_unstemmed | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol |
| title_short | Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol |
| title_sort | updates on the activity efficacy and emerging mechanisms of resistance to cefiderocol |
| topic | antimicrobials cefiderocol in vitro activity multidrug resistance Gram-negative emerging resistance |
| url | https://www.mdpi.com/1467-3045/46/12/846 |
| work_keys_str_mv | AT gabrielebianco updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT matteoboattini updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT monicacricca updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT luciadiella updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT milogatti updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT lucarossi updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT michelebartoletti updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT vittoriosambri updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT caterinasignoretto updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT rossellafonnesu updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT saracomini updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol AT paologaibani updatesontheactivityefficacyandemergingmechanismsofresistancetocefiderocol |